Vienna, Austria

ESTRO 2023

Session

Monday
May 15
08:45 - 10:00
Hall A
This house believes that internal mammary node irradiation of high-risk breast cancer should be the standard of care today
Philip Poortmans, Belgium;
Pierfrancesco Franco, Italy
In this fierce debate, experienced colleagues will explain us whether the level-1 evidence demonstrated effects of regional nodal irradiation (RNI) in decreasing relapses and improving survival for breast cancer patients continue outweighing possible late toxicity in the present era of more effective systemic therapies. We will be asked how we can identify the specific internal mammary (IM) irradiation benefit as component of RNI? What is the impact of more individualised RNI techniques, on both efficacy and toxicity, especially in view of contemporary systemic agents? How can we fit individualisation of indications, prescriptions, and techniques in the ongoing trend of decreasing surgical extent? So, let you take away by the debaters, absorb and process all information and finally decide and vote for yourself whether you agree or not with the statement that IM irradiation should be standard of care for high-risk breast cancer patients!
Debate
Clinical
08:48 - 09:03
Birgitte Offersen, Denmark
SP-0693
09:03 - 09:18
Duncan Wheatley, United Kingdom
SP-0694
09:18 - 09:33
Orit Kaidar-Person, Israel
SP-0695
09:33 - 09:48
Meritxell Arenas, Spain
SP-0696